Edwards Lifesciences (EW) Long-Term Investments (2009 - 2026)

Edwards Lifesciences' Long-Term Investments history runs 18 years deep, the most recent figure standing at $285.6 million for Q1 2026.

• On a quarterly basis, Long-Term Investments rose 2.77% year-over-year to $285.6 million in Q1 2026; TTM through Mar 2026 was $285.6 million, a 2.77% increase from a year earlier, with the FY2025 full-year figure at $278.6 million, down 9.52% from the prior year.
• Long-Term Investments advanced to $285.6 million in Q1 2026 per EW's latest filing, from $278.6 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $1.6 billion in Q1 2022 and bottomed at $274.7 million in Q3 2025.
• The 5-year median for Long-Term Investments is $455.6 million (2024), against an average of $694.0 million.
• Across the five-year window, Long-Term Investments soared 102.41% in 2022 and plunged 58.74% in 2024, its largest moves.
• Year by year, Long-Term Investments stood at $1.2 billion in 2022, then slumped by 52.87% to $583.9 million in 2023, then tumbled by 47.27% to $307.9 million in 2024, then retreated by 9.52% to $278.6 million in 2025, then climbed by 2.51% to $285.6 million in 2026.
• Per Business Quant, the three latest EW Long-Term Investments figures stand at $285.6 million (Q1 2026), $278.6 million (Q4 2025), and $274.7 million (Q3 2025).